Skip to main content
. Author manuscript; available in PMC: 2018 Jul 8.
Published in final edited form as: Clin Cancer Res. 2016 Sep 6;23(5):1167–1176. doi: 10.1158/1078-0432.CCR-16-0772

Figure 2.

Figure 2

Observed antitumor responses in DLBCL patients (A) and iNHL patients (B). Dashed lines indicate 50% increases and 50% decreases in SPD from baseline. R, refractory; SPD, sum of the product of the diameters.